The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer
Philip J. Saylor, Sergey V. Kozin, Aya Matsui, Saveli Goldberg, Shuichi Aoki, Kohei Shigeta, Émilie Mamessier, Matthew R. Smith, M. Dror Michaelson, Richard J. Lee, Dan G. Duda
Topics & Concepts
Prostate cancerRadium-223MedicineOncologyInternal medicineCancer researchCancerBone metastasisRadiopharmaceutical Chemistry and ApplicationsCancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research